Revolution Historical Income Statement

RVMDW Stock

0.32 0.08 20.00%

Historical analysis of Revolution Medicines, income statement accounts such as Total Revenue of 11 M, Research Development of 243.4 M, Total Operating Expenses of 284.2 M or Reconciled Depreciation of 8.3 M can show how well Revolution Medicines, Warrant performed in making a profits. Evaluating Revolution Medicines, income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Revolution Medicines,'s future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Revolution Medicines, latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Revolution Medicines, is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revolution Medicines, Warrant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

About Revolution Income Statement Analysis

Revolution Medicines, Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Revolution Medicines, shareholders. The income statement also shows Revolution investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Revolution Medicines, Income Statement Chart

At this time, Revolution Medicines,'s Net Interest Income is fairly stable compared to the past year. Interest Income is likely to climb to about 49.9 M in 2024, whereas Interest Expense is likely to drop slightly above 287.9 K in 2024.

Interest Expense Selling General Administrative Total Revenue Operating Income Total Operating Expenses Income Before Tax

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Total Revenue

Total revenue comprises all receipts Revolution Medicines, generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Operating Income

Operating Income is the amount of profit realized from Revolution Medicines, operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Revolution Medicines, Warrant is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Revolution Medicines, income statement and is an important metric when analyzing Revolution Medicines, profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Most accounts from Revolution Medicines,'s income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Revolution Medicines, current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revolution Medicines, Warrant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

	2021	2022	2023	2024 (projected)
Interest Income	929K	9.2M	47.5M	49.9M
Net Interest Income	917K	9.2M	47.2M	49.5M

Interest Income Net Interest Income

Revolution Medicines, income statement Correlations

	Tax Provision	Net Interest Income	Interest Income	Interest Expense	Selling General Administrative	Total Revenue	Operating Income	Net Income From Continuing Ops	Research Development	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Net Income	Depreciation And Amortization	Gross Profit	Other Operating Expenses	Ebit	Ebitda	Cost Of Revenue	Total Other Income Expense Net	Income Tax Expense	Selling And Marketing Expenses
Tax Provision		0.09	0.09	0.49	0.39	-0.4	-0.36	-0.41	0.42	0.42	0.71	-0.39	-0.4	0.5	0.67	0.34	-0.32	-0.32	-0.23	0.11	-0.53	-0.06
Net Interest Income	0.09		1.0	0.03	0.83	-0.92	-0.95	-0.93	0.83	0.83	0.69	-0.94	-0.94	0.77	0.63	0.87	-0.96	-0.96	0.91	1.0	-0.43	-0.94
Interest Income	0.09	1.0		0.03	0.83	-0.92	-0.95	-0.93	0.82	0.83	0.69	-0.94	-0.94	0.77	0.63	0.87	-0.95	-0.96	0.91	1.0	-0.43	-0.95
Interest Expense	0.49	0.03	0.03		0.28	-0.12	-0.23	-0.26	0.33	0.32	0.59	-0.25	-0.26	0.62	0.5	0.28	-0.23	-0.23	-0.31	0.04	0.11	0.07
Selling General Administrative	0.39	0.83	0.83	0.28		-0.89	-0.92	-0.93	1.0	1.0	0.87	-0.93	-0.93	0.87	0.8	0.99	-0.92	-0.92	0.61	0.84	-0.53	-0.63
Total Revenue	-0.4	-0.92	-0.92	-0.12	-0.89		0.98	0.98	-0.89	-0.89	-0.84	0.98	0.98	-0.84	-0.85	-0.91	0.98	0.98	-0.72	-0.93	0.72	0.87
Operating Income	-0.36	-0.95	-0.95	-0.23	-0.92	0.98		1.0	-0.93	-0.93	-0.87	1.0	1.0	-0.9	-0.84	-0.95	1.0	1.0	-0.74	-0.95	0.58	0.87
Net Income From Continuing Ops	-0.41	-0.93	-0.93	-0.26	-0.93	0.98	1.0		-0.93	-0.93	-0.89	1.0	1.0	-0.92	-0.86	-0.95	1.0	1.0	-0.7	-0.94	0.6	0.85
Research Development	0.42	0.83	0.82	0.33	1.0	-0.89	-0.93	-0.93		1.0	0.89	-0.93	-0.93	0.89	0.82	0.99	-0.93	-0.92	0.58	0.83	-0.54	-0.63
Total Operating Expenses	0.42	0.83	0.83	0.32	1.0	-0.89	-0.93	-0.93	1.0		0.89	-0.93	-0.93	0.89	0.82	0.99	-0.93	-0.92	0.59	0.83	-0.54	-0.63
Reconciled Depreciation	0.71	0.69	0.69	0.59	0.87	-0.84	-0.87	-0.89	0.89	0.89		-0.89	-0.89	0.96	0.93	0.87	-0.86	-0.86	0.35	0.7	-0.55	-0.57
Income Before Tax	-0.39	-0.94	-0.94	-0.25	-0.93	0.98	1.0	1.0	-0.93	-0.93	-0.89		1.0	-0.91	-0.85	-0.95	1.0	1.0	-0.71	-0.94	0.6	0.85
Net Income	-0.4	-0.94	-0.94	-0.26	-0.93	0.98	1.0	1.0	-0.93	-0.93	-0.89	1.0		-0.92	-0.85	-0.95	1.0	1.0	-0.71	-0.94	0.59	0.85
Depreciation And Amortization	0.5	0.77	0.77	0.62	0.87	-0.84	-0.9	-0.92	0.89	0.89	0.96	-0.91	-0.92		0.9	0.89	-0.9	-0.9	0.44	0.78	-0.44	-0.65
Gross Profit	0.67	0.63	0.63	0.5	0.8	-0.85	-0.84	-0.86	0.82	0.82	0.93	-0.85	-0.85	0.9		0.8	-0.83	-0.83	0.26	0.65	-0.75	-0.57
Other Operating Expenses	0.34	0.87	0.87	0.28	0.99	-0.91	-0.95	-0.95	0.99	0.99	0.87	-0.95	-0.95	0.89	0.8		-0.95	-0.95	0.65	0.88	-0.52	-0.69
Ebit	-0.32	-0.96	-0.95	-0.23	-0.92	0.98	1.0	1.0	-0.93	-0.93	-0.86	1.0	1.0	-0.9	-0.83	-0.95		1.0	-0.75	-0.96	0.57	0.87
Ebitda	-0.32	-0.96	-0.96	-0.23	-0.92	0.98	1.0	1.0	-0.92	-0.92	-0.86	1.0	1.0	-0.9	-0.83	-0.95	1.0		-0.75	-0.96	0.58	0.87
Cost Of Revenue	-0.23	0.91	0.91	-0.31	0.61	-0.72	-0.74	-0.7	0.58	0.59	0.35	-0.71	-0.71	0.44	0.26	0.65	-0.75	-0.75		0.9	-0.21	-0.89
Total Other Income Expense Net	0.11	1.0	1.0	0.04	0.84	-0.93	-0.95	-0.94	0.83	0.83	0.7	-0.94	-0.94	0.78	0.65	0.88	-0.96	-0.96	0.9		-0.44	-0.94
Income Tax Expense	-0.53	-0.43	-0.43	0.11	-0.53	0.72	0.58	0.6	-0.54	-0.54	-0.55	0.6	0.59	-0.44	-0.75	-0.52	0.57	0.58	-0.21	-0.44		0.45
Selling And Marketing Expenses	-0.06	-0.94	-0.95	0.07	-0.63	0.87	0.87	0.85	-0.63	-0.63	-0.57	0.85	0.85	-0.65	-0.57	-0.69	0.87	0.87	-0.89	-0.94	0.45

Click cells to compare fundamentals

Revolution Medicines, Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Revolution Stock Analysis

When running Revolution Medicines,'s price analysis, check to measure Revolution Medicines,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revolution Medicines, is operating at the current time. Most of Revolution Medicines,'s value examination focuses on studying past and present price action to predict the probability of Revolution Medicines,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revolution Medicines,'s price. Additionally, you may evaluate how the addition of Revolution Medicines, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Revolution Historical Income Statement

About Revolution Income Statement Analysis

Revolution Medicines, Income Statement Chart

Interest Expense

Total Revenue

Operating Income

Total Operating Expenses

Income Before Tax

Revolution Medicines, income statement Correlations

Revolution Medicines, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Revolution Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Interest Income	+ 1.0	Net Interest Income
Total Other Income Expense Net	+ 1.0	Net Interest Income
Total Other Income Expense Net	+ 1.0	Interest Income
Research Development	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Selling General Administrative
Net Income From Continuing Ops	+ 1.0	Operating Income

Total Other Income Expense Net	- 0.96	Ebitda
Total Other Income Expense Net	- 0.96	Ebit
Ebitda	- 0.96	Interest Income
Ebitda	- 0.96	Net Interest Income
Ebit	- 0.96	Net Interest Income
Ebitda	- 0.95	Other Operating Expenses